Characteristics of Late-Onset Spondyloarthritis: Data from the Moroccan Registry of Biological Therapies in Rheumatic Diseases.

characteristics diagnosis late onset registry spondyloarthritis

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
May 2023
Historique:
accepted: 16 05 2023
medline: 5 6 2023
pubmed: 5 6 2023
entrez: 5 6 2023
Statut: epublish

Résumé

Introduction The Assessment of SpondyloArthritis International Society (ASAS) criteria for axial and peripheral spondyloarthritis (SpA) allow for the classification of patients with an age of onset of disease of less than 45 years. However, SpA can start after this age. This study aimed to assess the characteristics of late-onset SpA (SpA>45 years) in the Moroccan registry of biological therapies in rheumatic diseases (RBSMR). Methods A cross-sectional study was conducted using the baseline data of the RBSMR. The protocol for the original RBSMR study was reviewed and approved by the Ethics Committee for Biomedical Research Mohammed V University - Rabat, Faculty of Medicine and Pharmacy of Rabat (approval number for the study was 958/09/19, and the date of approval was September 11, 2019), and all patients had given their written consent. Patients who met the 2009 ASAS criteria for SpA were included. They were divided into two groups: early-onset SpA (≤ 45 years) and late-onset SpA (>45 years). Clinical, biological, radiological, and therapy data of the two groups were compared. Statistical analysis was performed using SPSS v25 software (IBM Corp. Armonk, NY). Parameters with a p-value ≤0.05 were considered significant. Results Our population consisted of 194 patients. Thirty-one patients (16%) had late-onset SpA. Comparison between patients with early-onset (≤45 years) and late-onset SpA (>45 years) revealed that late-onset SpA had a higher tender joint count (p=0.01), a higher swollen joint count (p=0.02), depression (p=0.00), fibromyalgia (p=0.001), hypercholesterolemia (p=0.01), and a lower frequency of coxitis (p=0.008). Logistic regression analysis confirmed that late-onset SpA was associated with a higher tender joint count (OR=0.93, CI 95%: 0.88-0.98), a higher swollen joint count (OR=0.92, CI 95%: 0.85-0.99), depression ( OR=0.19, CI 95%:0.04-0.38), fibromyalgia (OR=1.75, CI 95%: 1.74-17.85), and a lower frequency of coxitis ( OR=0.29, CI 95%: 0.11-0.75). Conclusion As life expectancy increases, late-onset SpA will become increasingly common. It is therefore imperative to determine its characteristics. In the RBSMR study, late-onset SpA was associated with a high number of tender and swollen joints, depression, fibromyalgia, and a lower frequency of coxitis.

Identifiants

pubmed: 37273389
doi: 10.7759/cureus.39100
pmc: PMC10234029
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e39100

Informations de copyright

Copyright © 2023, Mougui et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

ISRN Rheumatol. 2011;2011:840475
pubmed: 23509636
Drugs Aging. 2015 Jul;32(7):515-24
pubmed: 26123949
Ann Rheum Dis. 1997 Sep;56(9):572
pubmed: 9370890
Rheumatol Int. 2018 Mar;38(3):425-432
pubmed: 29299630
Ann Rheum Dis. 2006 Nov;65(11):1518-20
pubmed: 16464987
Drugs Aging. 2005;22(6):451-69
pubmed: 15974637
Curr Rheumatol Rep. 2013 Aug;15(8):345
pubmed: 23771558
J Am Acad Dermatol. 1985 Sep;13(3):450-6
pubmed: 4056119
Curr Rheumatol Rep. 2017 Feb;19(2):8
pubmed: 28197884
Medicine (Baltimore). 2019 Feb;98(7):e14431
pubmed: 30762750
Bosn J Basic Med Sci. 2015 Jul 22;15(3):64-7
pubmed: 26295296
Sci Rep. 2021 Jun 29;11(1):13536
pubmed: 34188149
J Rheumatol. 2012 May;39(5):1008-12
pubmed: 22422491
Ann Rheum Dis. 2009 Jun;68(6):777-83
pubmed: 19297344
Clin Rheumatol. 2012 Nov;31(11):1599-603
pubmed: 22895877
Scand J Rheumatol. 1995;24(5):314-5
pubmed: 8533048
Curr Opin Rheumatol. 2020 Jul;32(4):321-329
pubmed: 32453039
Curr Rheumatol Rep. 2013 Dec;15(12):374
pubmed: 24170254
Clin Exp Rheumatol. 2012 May-Jun;30(3):351-7
pubmed: 22510473
Mod Rheumatol. 2018 Jan;28(1):174-181
pubmed: 28569568
Drugs Aging. 2019 Oct;36(10):909-925
pubmed: 31250280
Rev Rhum Mal Osteoartic. 1992 Sep;59(6 Pt 2):37S-42S
pubmed: 1485129

Auteurs

Ahmed Mougui (A)

Rheumatology, EzarriHospital, Faculty of Medicine and Pharmacy of Marrakech, Mohammed VI University Hospital, Marrakech, MAR.

Zineb Baba (Z)

Rheumatology, Arrazi Hospital, Faculty of Medicine and Pharmacy of Marrakech, Mohammed VI University Hospital, Marrakech, MAR.

Ihsane Hmamouchi (I)

Laboratory of Biostatistics, Clinical Research and Epidemiology, Mohammed V University, Rabat, MAR.

Redouane Abouqal (R)

Laboratory of Biostatistics, Clinical Research and Epidemiology., Mohammed V University, Rabat, MAR.

Ahmed Bezza (A)

Rheumatology, Military Hospital Mohammed V, Ibn Sina University Hospital, Rabat, MAR.

Fadoua Allali (F)

Rheumatology B, El Ayachi Hospital, Ibn Sina University Hospital, University Mohamed V, Rabat, MAR.

Rachid Bahiri (R)

Rheumatology A, El Ayachi Hospital, Ibn Sina University Hospital, University Mohamed V, Rabat, MAR.

Imad Ghozlani (I)

Rheumatology, Faculty of Medicine and Pharmacy, University Ibn Zohr, Agadir, MAR.

Hasna Hassikou (H)

Rheumatology, Military Hospital Moulay Ismail, Hassan II University Hospital, Meknes, MAR.

Linda Ichchou (L)

Rheumatology, Mohammed VI University Hospital, Mohammed I University, Oujda, MAR.

Saadia Janani (S)

Rheumatology, Ibn Rochd University Hospital, Casablanca, Morocco, Casablanca, MAR.

Taoufik Harzy (T)

Rheumatology, Hassan II University Hospital, Fes, MAR.

Redouane Niamane (R)

Rheumatology, Military Hospital Avicenne, Mohammed VI University Hospital, Marrakech, MAR.

Abdellah El Maghraoui (A)

Rheumatology, Private Medical Office, Rabat, MAR.

Imane El Bouchti (I)

Rheumatology, Ezarri Hospital, Faculty of Medicine and Pharmacy of Marrakech, Mohammed VI University Hospital, Marrakech, MAR.

Classifications MeSH